Atom | Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33

Funder: National Institutes of Health

Due Dates: June 18, 2025 (New/Renewal/Resubmission/Revision) | August 21, 2025 (AIDS) | October 21, 2025 (New/Renewal/Resubmission/Revision) | December 22, 2025 (AIDS) | Additional cycles through December 2027

Funding Amounts: Up to $300,000 direct costs/year for R61 and R33 phases; max 3 years total (≤2 years per phase); R33 phase requires 0.25:1 non-federal cash match.

Summary: Early-stage translational support for medical device prototype design/testing, disease target identification, and assay/tool development for heart, lung, blood, and sleep disorders.

Key Information: Clinical trials are not allowed; R33 phase requires cost matching and an Accelerator Partner for commercialization guidance.

Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)

Sign in to see full grant listing